Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Zymeworks Inc. Director's Dealing 2026

Feb 2, 2026

32180_dirs_2026-02-02_f96f4293-4edf-4051-9dc1-647043365e77.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Zymeworks Inc. (ZYME)
CIK: 0001937653
Period of Report: 2026-02-01

Reporting Person: Mekan Sabeen (N/A)

Holdings (Non-Derivative)

Security Shares Ownership
No securities are beneficially owned 0 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $11.75 2035-04-20 Common Stock (192000) Direct
Stock Option (Right to Buy) $23.16 2036-01-11 Common Stock (29000) Direct
Restricted Stock Unit $ Common Stock (19000) Direct
Performance Stock Unit $ Common Stock (32000) Direct

Footnotes

F1: Stock option granted April 21, 2025.

F2: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.

F3: Stock option granted January 12, 2026.

F4: Restricted stock units ("RSUs") granted January 12, 2026. RSUs vest in four equal annual installments beginning on first anniversary of grant date.

F5: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock.

F6: Performance restricted stock units ("PSUs") granted January 12, 2026. Each PSU represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 16,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index.

F7: (Continued from footnote 6) The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control).